← Back to Search

Loteprednol for Post-Injection Pain in Age-Related Macular Degeneration

N/A
Recruiting
Led By Romulo Albuquerque, M.D., Ph.D.
Research Sponsored by Virginia Polytechnic Institute and State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-day post-intravitreal injection

Summary

This trial studies if loteprednol can reduce pain after intravitreal injections for age-related macular degeneration. Participants will get either loteprednol or artificial tears and pain levels will be monitored over 1 week.

Who is the study for?
This trial is for adults with age-related macular degeneration who are getting intravitreal injections. They must not have dementia, report baseline eye pain, use certain eye medications, be under 18, have specific eye conditions like advanced glaucoma or a history of pressure increases due to steroids, allergies to study drugs, chronic pain disorders, herpes zoster; they also can't be pregnant or incarcerated.
What is being tested?
The trial tests if loteprednol (a corticosteroid) drops can reduce pain after intravitreal injections compared to artificial tears. Participants will receive one of the treatments and report their pain levels over a week via phone calls.
What are the potential side effects?
Loteprednol may cause increased eye pressure in some people and has potential side effects typical of steroids such as blurred vision, cataracts formation or risk of infection in the eyes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-day post-intravitreal injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-day post-intravitreal injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain
Secondary study objectives
Analgesics
Lubricant Eye Drops

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LoteprednolExperimental Treatment1 Intervention
1 drop of Loteprednol is administered immediately after the intravitreal injection in this treatment arm.
Group II: Artificial tearsPlacebo Group1 Intervention
1 drop of artificial tears is administered immediately after the intravitreal injection in this treatment arm. This arm acts as a negative control.

Find a Location

Who is running the clinical trial?

Virginia Polytechnic Institute and State UniversityLead Sponsor
153 Previous Clinical Trials
25,033 Total Patients Enrolled
Vistar Eye CenterOTHER
Romulo Albuquerque, M.D., Ph.D.Principal InvestigatorVistar Eye Center

Media Library

Loteprednol Clinical Trial Eligibility Overview. Trial Name: NCT05542381 — N/A
Age-Related Macular Degeneration Research Study Groups: Loteprednol, Artificial tears
Age-Related Macular Degeneration Clinical Trial 2023: Loteprednol Highlights & Side Effects. Trial Name: NCT05542381 — N/A
Loteprednol 2023 Treatment Timeline for Medical Study. Trial Name: NCT05542381 — N/A
~25 spots leftby Nov 2025